Company Overview and News

 
Workiva: Soaring To New Heights Despite Mediocre XBRL

2018-10-17 seekingalpha
Workiva grew revenues and client count in the second quarter, maintaining their position as the market leader in XBRL services.
DFIN WK DFIN.WI

 
Workiva Boosts Wdesk Platform With New Audit-Based Solutions

2018-09-20 zacks
Workiva Inc. (WK - Free Report) recently strengthened its flagship product, Wdesk platform, with new solutions for internal audit management. The announcement was made at Workiva User Conference during its opening session.
XLNX WK LB AZPN CRM SBAZ

247
Stocks To Watch: Oracle Looks To Lift Tech Sector

2018-09-15 seekingalpha - 5
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning.
DOVA GIS TXN CAT AZO TWX RCL OPRF MAS HABT SHAK SUM BOX SONC RCII ABBV USCR FOX REGN BAC SQ DFS TRV COF-P WK BX JACK SYF AIG WEN ALL IDA KNSA NVS ABBV MSFT FL ZOES PFE ADS FOXA MLM JD NIO ATH DRI CX PYPL AXP MCO JBHT BRO EXP USB BAC COF-D COF-C COF-F HIG AAPL VMC TSG ORCL DEO MCD BMY RRGB WBC C CMCSA O THO MA M COF FDX NAVG HUM SNY RHT DSKE JPM IBOC MU DHR

4
What Will You Miss Out On by Overlooking Workiva (WK) Stock?

2018-08-28 zacks - 1
Workiva Inc. (WK - Free Report) has exhibited impressive price performance over the last two years. The stock, which was valued at approximately $16.7 at the beginning of 2016, now trades close to $33, reflecting more than two-fold jump.
ECR SAP SAPGF WK LMHA LMHB AZPN LM PAYC

 
Top Ranked Momentum Stocks to Buy for August 14th

2018-08-14 zacks
Here are four stocks with buy rank and strong momentum characteristics for investors to consider today, August 14th:
TER WK TNAV

 
BlackLine: Strong Quarter With 32% Revenue Growth

2018-08-14 seekingalpha
BlackLine provides a cloud-based software platform, which helps organizations of all types and sizes modernize their accounting and finance operations.
BL DATA WK

1
Working On Workiva

2018-08-13 seekingalpha - 1
Investors would probably do well to avoid this company until there's some proof of consistent profitability.
WK

3
Billion-Dollar Unicorns: BlackLine Looks At International Markets

2018-08-09 seekingalpha
BlackLine is realizing the importance of international markets to deliver growth and has invested in its sales force to target these markets.
IBM BL SAP WK ORCL

 
Workiva: Not So Boring Anymore

2018-08-08 seekingalpha
Workiva, a little-known software company that primarily helps businesses with SEC compliance, soared after posting Q2 results.
WK

 
Workiva (WK) CEO Marty Vanderploeg on Q2 2018 Results - Earnings Call Transcript

2018-08-08 seekingalpha
Good afternoon. My name is Chris, and I'll be your conference operator today. At this time, I would like to welcome everyone to the Workiva Second Quarter 2018 Earnings Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question-and-answer session. [Operator Instructions].
WK

1
Workiva (WK) Reports Q2 Loss, Tops Revenue Estimates

2018-08-08 zacks
Workiva (WK - Free Report) just came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.14 per share a year ago. These figures are adjusted for non-recurring items.
KRO CIVI WK SBOW

 
WK / Workiva, Inc. 8-K (Current Report)

2018-08-08 sec.gov
Document UNITED STATES
WK

 
WK / Workiva, Inc. WORKIVA S-8

2018-08-08 sec.gov
Document As filed with the Securities and Exchange Commission on August 7, 2018
WK

1
Will Wdesk Cloud Platform Drive Workiva's (WK) Q2 Earnings?

2018-08-03 zacks
Workiva Inc. (WK - Free Report) is set to report second-quarter 2018 results on Aug 7. Notably, the company has surpassed the Zacks Consensus Estimate in the trailing four quarters, recording an average positive earnings surprise of 29.24%.
SAP JAZZ CY SAPGF PPL WK

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

Silicon Investor Message Boards

This table lists all message boards related to WK / Workiva, Inc. on message board site Silicon Investor.

2026 TeoTwawKi ... 2032 Darkest Interregnum 2026 TeoTwawKi ... 2032 Darkest Interregnum 2026 TeoTwawKi ... 2032 Darkest Interregnum UPWK - UpWork UPWK - UpWork UPWK - UpWork
SWKS - Skyworks Solutions, Inc (was AHAA) SWKS - Skyworks Solutions, Inc (was AHAA) SWKS - Skyworks Solutions, Inc (was AHAA) Blackhawk Network Holdings, Inc (HAWK) Blackhawk Network Holdings, Inc (HAWK) Blackhawk Network Holdings, Inc (HAWK)
Stanley Works (SWK) Stanley Works (SWK) Stanley Works (SWK) NTWK OTC BB Netsol International Inc (Formerly MGHI) NTWK OTC BB Netsol International Inc (Formerly MGHI) NTWK OTC BB Netsol International Inc (Formerly MGHI)
NewKidCo International (OTC:NKCIF) (TSE:NKC) NewKidCo International (OTC:NKCIF) (TSE:NKC) NewKidCo International (OTC:NKCIF) (TSE:NKC) HAWKEYE Gold Grants 985,000 Incentive Stock Options HAWKEYE Gold Grants 985,000 Incentive Stock Options HAWKEYE Gold Grants 985,000 Incentive Stock Options
HAWKEYE Gold Grants 985,000 Incentive Stock Options HAWKEYE Gold Grants 985,000 Incentive Stock Options HAWKEYE Gold Grants 985,000 Incentive Stock Options HAWKEYE GOLD PURCHASE TOP PROPERTY - YUKON HAWKEYE GOLD PURCHASE TOP PROPERTY - YUKON HAWKEYE GOLD PURCHASE TOP PROPERTY - YUKON
CUSIP: 98139A105